Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

NCT01845584 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: NPB-01

Sponsor

Nihon Pharmaceutical Co., Ltd